Bausch Health Companies (NYSE:BHC – Get Rating) will be issuing its quarterly earnings data before the market opens on Thursday, February 23rd. Analysts expect the company to announce earnings of $0.92 per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.
Bausch Health Companies Trading Up 19.3 %
→ There’s A Reason People Are Skeptical About The Groundhog… (From Base Camp Trading)
NYSE BHC opened at $8.98 on Thursday. The business’s 50-day moving average price is $7.41 and its two-hundred day moving average price is $6.91. Bausch Health Companies has a 12 month low of $4.00 and a 12 month high of $25.83. The firm has a market capitalization of $3.25 billion, a PE ratio of 12.83, a price-to-earnings-growth ratio of 0.11 and a beta of 1.06. The company has a current ratio of 1.05, a quick ratio of 0.77 and a debt-to-equity ratio of 48.05.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in BHC. Norges Bank acquired a new position in shares of Bausch Health Companies in the 4th quarter valued at about $20,553,000. Renaissance Technologies LLC lifted its stake in shares of Bausch Health Companies by 903.3% in the 1st quarter. Renaissance Technologies LLC now owns 1,153,789 shares of the company’s stock valued at $26,370,000 after purchasing an additional 1,038,789 shares during the period. Morgan Stanley raised its stake in Bausch Health Companies by 45.4% during the 4th quarter. Morgan Stanley now owns 1,596,167 shares of the company’s stock worth $10,024,000 after buying an additional 498,042 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in Bausch Health Companies by 330.2% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 540,515 shares of the company’s stock worth $12,348,000 after buying an additional 414,858 shares during the period. Finally, Vanguard Group Inc. raised its stake in Bausch Health Companies by 3.4% during the 1st quarter. Vanguard Group Inc. now owns 10,225,558 shares of the company’s stock worth $233,653,000 after buying an additional 335,045 shares during the period. 66.99% of the stock is owned by institutional investors and hedge funds.
About Bausch Health Companies
Bausch Health Cos., Inc engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bausch Health Companies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Bausch Health Companies wasn’t on the list.
While Bausch Health Companies currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
